This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/chebi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/wikipedia/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/pharmgkb/
n15http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/drugbank/
n11http://www.drugs.com/cdi/
n10http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00539/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00539
rdf:type
n3:Drug
n3:description
A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]
n3:dosage
n19:271B41D8-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Price N, Sartor O, Hutson T, Mariani S: Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):211-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15882476 # Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA: Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16503765 # Thompson IM: Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep;178(3 Pt 2):S9-S13. Epub 2007 Jul 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17644117 # Ariazi EA, Ariazi JL, Cordera F, Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6(3):181-202. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16515478 # Musa MA, Khan MO, Cooperwood JS: Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14(11):1249-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17504144
n3:group
approved investigational
n3:halfLife
5 days
n3:indication
For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
n3:manufacturer
n4:271B41D6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00539 n17:DB00539
dcterms:title
Toremifene
adms:identifier
n13:9635 n16:Toremifene n20:C08166 n21:11399-005-30 n22:2275722 n23:DB00539 n24:46506087 n25:PA451731 n26:3005573
n3:mechanismOfAction
Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors.
n3:packager
n4:271B41D5-363D-11E5-9242-09173F13E4C5
n3:patent
n18:4696949
n3:routeOfElimination
Toremifene is extensively metabolized, principally by CYP3A4 to N-demethyltoremifene, which is also antiestrogenic but with weak in vivo antitumor potency.
n3:synonym
Toremifenum Toremifeno
n3:volumeOfDistribution
* 580 L
n3:proteinBinding
Toremifen is primarily bound to albumin (92%), 2% bound to α1-acid glycoprotein, and 6% bound to β1-globulin in the serum.
n3:synthesisReference
Reijo Toivola, Tuomas Huuhtanen, "Toremifene crystallization method." U.S. Patent US20070093556, issued April 26, 2007.
foaf:page
n10:toremifene.htm n11:toremifene.html
n3:IUPAC-Name
n5:271B41DD-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B41E3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B41E2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B41DF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B41E0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B41E1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B41DB-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B41F3-363D-11E5-9242-09173F13E4C5 n5:271B41DC-363D-11E5-9242-09173F13E4C5 n5:271B41D9-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B41DA-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:L02BA02
n3:H-Bond-Acceptor-Count
n5:271B41E9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B41EA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B41E4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B41E5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B41E7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B41E6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B41E8-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
89778-26-7
n3:category
n3:clearance
* 5 L/h
n3:containedIn
n8:271B41D7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B41EE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B41F0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B41F1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B41F2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B41ED-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B41EC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B41EF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B41DE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B41EB-363D-11E5-9242-09173F13E4C5